Generics

WASHINGTON — Rx Response late Monday announced it has activated its Pharmacy Reporting Status Tool to aid storm managers and people in communities affected by Hurricane Irene.

NEW YORK — Mylan will be banned temporarily from launching a generic drug for acne pending a federal court's decision whether or not to bar it, according to published reports.

SCHAUMBURG, Ill. — Jonathon Singer has been appointed CFO of Sagent Pharmaceuticals, the generic drug maker said.

Singer joins Sagent from Landauer, a leader in radiation sciences and services, where he served as SVP finance and CFO. Meanwhile, Sagent's current CFO, Ron Pauli, will be transitioned into a newly created role of chief business officer, where he will be responsible for product launch execution, product pipeline management and business development.

HYDERABAD, India — Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

Dr. Reddy’s will market the product, the equivalent to Allegra-D 24 Hour, under store-brand labels in the U.S. market, the company stated.

Quarterly sales of Allegra-D totaled $13.5 million for the 12 weeks ended Aug. 7, according to SymphonyIRI Group tabulating sales across food, drug and mass (minus Walmart) outlets.

ALLEGAN, Mich. — The Food and Drug Administration has approved a treatment for dermatitis made by Perrigo under a collaboration with Chicago-based Cobrek Pharmaceutical.

The drug maker said Tuesday that the FDA approved ketoconazole foam in the 2% strength. The drug is a generic version of Stiefel Labs' Extina, a topical drug used to treat seborrheic dermatitis in patients ages 12 years and older with healthy immune systems.

Extina has annual sales of about $10 million, according to Perrigo.

JERUSALEM — A federal court has acted in favor of Teva Pharmaceutical Industries in the drug maker's patent infringement case against several generic drug companies seeking to market versions of its multiple sclerosis drug.

ATLANTA — Increases in vaccination rates for the human papillomavirus are trailing increases in rates for two other vaccines recommended for teens and preteens, according to data from the Centers for Disease Control and Prevention released Thursday.

Coverage rates for the other two vaccines — Tdap, which protects against tetanus, diphtheria and pertussis; and MenACWY, which protects against meningococcal meningitis — are continuing to increase, but vaccination rates for HPV vaccine remain low, the study found.

WASHINGTON — The U.S. Department of Health and Human Services on Thursday awarded $137 million to states to boost prevention and public health initiatives, including support for smoking-cessation programs and vaccinations.

Awarded in nearly every state, the grants enhance state, tribal, local and territorial efforts to provide tobacco cessation services, strengthen public health laboratory and immunization services, prevent healthcare-associated infections, and provide comprehensive substance abuse prevention and treatment.